Welcome to our dedicated page for Monopar Therapeutics news (Ticker: MNPR), a resource for investors and traders seeking the latest updates and insights on Monopar Therapeutics stock.
Monopar Therapeutics Inc. develops clinical and preclinical biopharmaceutical programs for Wilson disease and oncology radiopharmaceuticals. News about MNPR centers on ALXN1840, also described as tiomolibdate choline, a late-stage investigational oral therapy for Wilson disease, including analyses from the Phase 3 FoCus trial, copper-balance data, neurology and hepatology conference presentations, and related peer-reviewed publications.
Company updates also cover the MNPR-101 radiopharmaceutical programs for uPAR-expressing cancers, including MNPR-101-Zr imaging activity, MNPR-101-Lu therapeutic development and IND clearance, and preclinical MNPR-101-Ac work. Recurring corporate themes include financial results, public offerings, balance-sheet updates, and commercial or executive infrastructure as the company advances its pipeline.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Monopar Therapeutics Inc. (Nasdaq: MNPR) announced that Dr. Chandler Robinson, the CEO, will present at the Jefferies Radiopharma Innovation Summit on April 3, 2023, from 1:00 to 1:30 pm at the Jefferies Conference Center in NYC.
The company focuses on developing therapeutics aimed at extending life and improving the quality of life for cancer patients. Their pipeline includes camsirubicin (Phase 1b) for advanced soft tissue sarcoma and MNPR-101 for radiopharmaceutical use in advanced cancers. Monopar is committed to enhancing cancer patient care through innovation.
Monopar Therapeutics Inc. (Nasdaq: MNPR) announced the completion of a pre-specified interim analysis for its Phase 2b/3 VOICE trial, which aimed to prevent severe oral mucositis in patients with oropharyngeal cancer undergoing chemoradiotherapy. The independent Data Safety Monitoring Board reported that the trial did not meet the pre-defined efficacy threshold of a 15% absolute difference in SOM prevention between Validive and placebo, leading to the discontinuation of the study and Validive's development. Monopar plans to redirect resources towards advancing its Phase 1b camsirubicin trial and MNPR-101 radiopharmaceutical program, stating it has sufficient funds to support activities beyond Q1 2024.
Monopar Therapeutics (Nasdaq: MNPR) announced its financial results for Q4 and full year 2022. As of December 31, 2022, cash and investments totaled $13.1 million, expected to fund ongoing trials. The VOICE trial anticipates an interim analysis by next week to determine continuation. The camsirubicin Phase 1b trial has begun enrolling at a higher dose level, showing promising data in progression-free survival and lower toxicity than doxorubicin. Recent preclinical studies on MNPR-101 and MNPR-202 indicate potential advancements. However, a net loss of $10.5 million was reported for 2022.
Monopar Therapeutics (Nasdaq: MNPR), a biopharmaceutical company dedicated to cancer therapeutics, announced that CEO Chandler Robinson will participate in a fireside chat at the 35th Annual Roth Conference.
Event Details:
Date: March 13, 2023
Time: 12:30-1:00 pm PT
Location: The Ritz Carlton, Laguna Niguel, Dana Point, California.
Monopar's pipeline includes Validive® (Phase 2b/3) for severe oral mucositis, camsirubicin (Phase 1b) for soft tissue sarcoma, and MNPR-101 & MNPR-202 for advanced cancers. For more information, visit www.monopartx.com.
Monopar Therapeutics (Nasdaq: MNPR) and NorthStar Medical Radioisotopes have expanded their collaboration in the radiopharmaceutical sector, introducing a new imaging candidate, MNPR-101-Zr. Preclinical results indicate high uptake of MNPR-101-Zr in various tumors, supporting plans for a first-in-human imaging study by year-end. MNPR-101-Zr is a zirconium-89 labeled form of MNPR-101, targeted at the urokinase plasminogen activator receptor (uPAR). The partnership aims to leverage MNPR-101 for both imaging and therapeutic applications, highlighting the potential of personalized medicine in cancer treatment.
Monopar Therapeutics Inc. (Nasdaq: MNPR) has announced an update on its Phase 1b trial of camsirubicin for advanced soft tissue sarcoma (ASTS). Enrollment has begun for the fifth dose cohort at 650 mg/m2, nearly 2.5 times the highest dose previously evaluated. Notably, there has been no drug-related cardiotoxicity observed, in contrast to doxorubicin, the current standard treatment. Additionally, lower rates of hair loss and oral mucositis have been reported in patients treated with camsirubicin compared to those on doxorubicin. A second clinical trial site has also been established at the Fred Hutchinson Cancer Center in Seattle.